These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 10677923)
1. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy. Wu TT; Wang JS; Lu CM; Lee YH; Huang JK Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923 [TBL] [Abstract][Full Text] [Related]
2. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
3. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Kupelian P; Katcher J; Levin H; Zippe C; Klein E Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737 [TBL] [Abstract][Full Text] [Related]
4. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877 [TBL] [Abstract][Full Text] [Related]
5. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328 [TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer. Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667 [TBL] [Abstract][Full Text] [Related]
7. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. Noguchi M; Stamey TA; McNeal JE; Yemoto CM J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712 [TBL] [Abstract][Full Text] [Related]
8. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
9. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793 [TBL] [Abstract][Full Text] [Related]
10. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379 [TBL] [Abstract][Full Text] [Related]
11. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population. Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856 [TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941 [TBL] [Abstract][Full Text] [Related]
13. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy. Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734 [TBL] [Abstract][Full Text] [Related]
14. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255 [TBL] [Abstract][Full Text] [Related]
16. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Bauer JJ; Connelly RR; Sesterhenn IA; Bettencourt MC; McLeod DG; Srivastava S; Moul JW Cancer; 1997 Mar; 79(5):952-62. PubMed ID: 9041158 [TBL] [Abstract][Full Text] [Related]
17. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435 [TBL] [Abstract][Full Text] [Related]
18. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC; J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735 [TBL] [Abstract][Full Text] [Related]
19. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer. Valicenti RK; Chervoneva I; Gomella LG Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1093-7. PubMed ID: 15001249 [TBL] [Abstract][Full Text] [Related]
20. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. Patel DA; Presti JC; McNeal JE; Gill H; Brooks JD; King CR J Clin Oncol; 2005 Sep; 23(25):6157-62. PubMed ID: 16135482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]